. A. Clinical aspect reveled a nodular lesion covered with normal epithelium situated in buccal mucosa. B. The macroscopic appearance of the specimen was grayish and white, had an irregular surface, and measured 1.0 centimeter in diameter. method, x100 original magnification). B. S100 protein positive in cytoplasm distributed in some chondroid and connective cells (sABC method, x100 original magnification). C. Focally positive cytoplasm reaction for glial fibrillary acidic protein in chondroid and connective tissue area (sABC method, x200 original magnification). D. Cytoplasm tumor cells were positive for CD57 in chondroid and connective tissue area (sABC method, x100 original magnification). E. Focal positive cytoplasm cells for desmin in chondroid and connective tissue area (sABC method, x200 original magnification). F. Cytoplasm tumor spindle cells were focally positive for smooth muscle actin in connective tissue area (sABC method, x200 original magnification).
CAN YOU MAKE THE DIAGNOSIS?
A. extraskeletal chondroma B. pleomorphic adenoma C. soft-tissue chondromyxoid fibroma D. ectomesenchymal chondromyxoid tumor Ectomesenchymal chondromyxoid tumor (ECT) is an uncommon, benign, mesenchymal, soft-tissue neoplasm of the oral mucosa. ECT was first described in 1995, 1 with 52 cases reported in the English-language literature: 50 cases were in the tongue; 1 was in the hard palate; and 1 was in the buccal mucosa.
1-8 The cases described in the literature reported that ECT most commonly affects adults in the third to sixth decades of life. Clinically, ECT presents as a slow-growing, painless, firm, wellcircumscribed, submucosal nodule, covered by normal mucosa, that appears to involve only the oral cavity and usually is located on the anterior dorsum of the tongue.
2,9,10 Such tumors range in size from 0.3 to 2.0 cm.
9, 10 The diagnosis of ECT is grounded on clinical characteristics, light microscopy, and immunohistochemistry.
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The microscopic features (low-power microscopic analysis) reveal lobular sheets of cells surrounded by skeletal muscle fascicles and connective tissue. The lesion is not encapsulated, but loose connective tissue may be found at the interface between the tumor and normal tissue. Three different microscopic patterns are generally seen: cellular, myxoid, and chondroid matrix. Cellular areas are characterized by the proliferation of oval, polygonal, and spindle cells.
9 ECT may exhibit focal areas of cellular atypia, including pleomorphism and mitotic figures. 2 The immunopathologic characteristics indicate a tumor of mesenchymal, neurogenic origin 11 with the expression of vimentin, S100 protein, and GFAP. ECT presents variable immunoreactivity for CD57, desmin, and SMA, as we observed in the case described in this article.
9 Ki-67 protein labeling is low, indicating the benign nature of the tumor.
2 The presence of biphasic myxoid and chondroid patterns and the positivity of tumor cells for vimentin, S100 protein, and GFAP are important findings for making the diagnosis of ECT.
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The treatment for this tumor is conservative surgical excision. The recurrence rate of ECT is 7%. 9 In the follow-up of the case described in this article, the patient remained free of disease after 12 months, but the intraoral affected area exhibited paresthesia.
DIFFERENTIAL DIAGNOSIS
Extraskeletal chondroma. Extraskeletal chondroma is a benign, soft-tissue, cartilaginous tumor usually located in the hands and feet, 13 but it occasionally occurs in the head and neck region, in which the most reported sites are the paranasal sinuses, nasal cavity, larynx, and tongue.
14 Investigators have described extraskeletal chondroma as a cartilaginous choristoma owing to the presence of a tumorlike mass composed of "normal tissues" in an "abnormal location." 15 The histologic analysis reveals a well-circumscribed, lobulated mass composed of mature hyaline cartilage surrounded by condensed collagenous tissue. Some cellular atypia occasionally is observed. 16 In the immunohistochemical analysis, the cells are positive for S100 protein and vimentin as well as negative for pancytokeratin (AE1 and AE3), myoepithelial markers, and GFAP. The treatment of choice is local excision, and the recurrence rate is 10% to 15%. 17 Pleomorphic adenoma. Pleomorphic adenoma is the most common salivary gland tumor, accounting for approximately 60% of all salivary neoplasms. 18 The mean age of presentation is 40 years, but the age of patients with this condition can range from the first to the ninth decades of life.
19 Approximately 80% of pleomorphic adenomas arise in the parotid gland.
20
Clinically, these lesions are usually painless, slowgrowing tumors with a hard consistency, 21 measuring 2 to 5 cm in diameter. 20 There is a proliferation of epithelial and myoepithelial cells consisting of glandlike structures, ducts, cell nests, cords, spindle-shaped, and plasmacytoid cells, intermingled with a mesenchymal or chondromyxoid component with frequent metaplastic changes. The arrangement of these tissues varies from predominantly cellular to predominantly myxochondroid. 22 The tumor cells are positive for pancytokeratin and are variably positive for S100 protein, a-SMA, GFAP, calponin, CD10, and muscle-specific actin. Cells in the chondroid areas are positive for both vimentin and pancytokeratin. 20 Treatment is complete surgical excision. The recurrence rate as a carcinoma ex pleomorphic adenoma is nearly 3%. 23 Soft-tissue chondromyxoid fibroma. Soft-tissue chondromyxoid fibroma is a rare, benign, cartilaginous tumor that mostly arises from the metaphysis of long bones and rarely is seen in the head and neck region.
24
Investigators have reported the extension of the tumor to soft tissue. 25 However, to the best of our knowledge, investigators have described only 2 cases of a primary tumor with no bone involvement. 25, 26 In the histologic analysis, soft-tissue chondromyxoid fibroma exhibits a lobular pattern with stellate or spindle-shaped cells on a myxoid or chondroid background. The presence of mitosis is uncommon. Giant cells often are found at the periphery of the tumor. Immunohistochemically, the cells are positive for S100 protein, and the periphery of the chondroid area demonstrates positive staining for THE DIAGNOSIS D. ectomesenchymal chondromyxoid tumor ORIGINAL CONTRIBUTIONS SMA, muscle-specific actin (known as HHF-35), and CD34. 27 The prognosis of soft-tissue chondromyxoid fibroma has not been reported in the literature, likely owing to its rarity.
In addition to the neoplasms described previously, other important differential diagnoses for ECT include myoepithelioma, myxoid neurofibroma, and myxoid chondrosarcoma.
10 Myoepithelioma and ECT have some similar characteristics, but the clinical location and absence of salivary glands adjacent to ECT are important features that differentiate these 2 lesions.
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Furthermore, myoepithelioma is usually positive for a-SMA and does not present condromyxoid-exuberant areas.
1,9 Myxoid neurofibroma is a tumor with cells that contain wavy nuclei. Atypia or chondroid areas are not found in myxoid neurofibromas; nevertheless, both lesions express vimentin, S100 protein, and GFAP.
1,10
Extraskeletal myxoid chondrosarcoma typically exhibits more areas of cellular atypia and more aggressive clinical behavior than ECT.
10

CONCLUSIONS
In this article, we described the case of a patient with a nodular lesion on the left buccal mucosa who had a histopathologic diagnosis of ECT. A dental clinician can make the diagnosis of this type of rare oral neoplasm only through the combined analysis of clinical, histopathologic, and immunohistochemical characteristics. It is important to perform an accurate diagnosis of this type of lesion, because it may be confused with other lesions that have similar clinical features but a different prognosis. n
